Holen Sie sich die Stockscreener-App
10.20
1.26%
-0.13
Schlusskurs vom Vortag:
$10.33
Offen:
$10.46
24-Stunden-Volumen:
136.44K
Relative Volume:
0.69
Marktkapitalisierung:
$357.69M
Einnahmen:
$51.00M
Nettoeinkommen (Verlust:
$-8.73M
KGV:
-34.44
EPS:
-0.2962
Netto-Cashflow:
$-7.75M
1W Leistung:
-3.82%
1M Leistung:
-17.14%
6M Leistung:
+58.88%
1J Leistung:
+5.48%
1-Tages-Spanne:
$10.03
$10.49
1-Wochen-Bereich:
$10.03
$11.11
52-Wochen-Spanne:
$5.65
$13.25
Fennec Pharmaceuticals Inc Stock (FENC) Company Profile
Firmenname
Fennec Pharmaceuticals Inc
Sektor
Branche
Telefon
(919) 636-4530
Adresse
PO BOX 13628, RESEARCH TRIANGLE PARK, NC
Compare FENC vs VRTX, MRNA, REGN, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
FENC
Fennec Pharmaceuticals Inc
|
10.20 | 371.89M | 51.00M | -8.73M | -7.75M | -0.2962 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Fennec Pharmaceuticals Inc Stock (FENC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-12 | Eingeleitet | B. Riley Securities | Buy |
| 2026-01-09 | Eingeleitet | Piper Sandler | Overweight |
| 2022-11-22 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2022-09-07 | Eingeleitet | CapitalOne | Overweight |
| 2022-08-08 | Fortgesetzt | Craig Hallum | Buy |
| 2020-06-05 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-10-11 | Eingeleitet | Goldman | Buy |
Alle ansehen
Fennec Pharmaceuticals Inc Aktie (FENC) Neueste Nachrichten
Award shares leave restriction as Fennec Pharmaceuticals (FENC) CFO acquires 1,703 shares. - Stock Titan
Medical chief acquires 168 awarded shares at Fennec Pharmaceuticals (FENC), holding 9,687 directly. - Stock Titan
Commercial chief acquires 168 shares released from restriction at Fennec Pharmaceuticals (FENC). - Stock Titan
1,159 award shares released; Fennec Pharmaceuticals (FENC) CEO directly holds 67,461 shares afterward. - Stock Titan
(FENC) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Fennec Pharmaceuticals Reports PEDMARK Data Showing Reduced Hearing Loss in Japanese Study - Streetwise Reports
Fennec’s Pedmark Trial in Japan Shows Strong Hearing Protection Without Hurting Tumor Response - TipRanks
Fennec Pharmaceuticals Inc. - Baystreet.ca
Stocks in play: Fennec Pharmaceuticals Inc. - Yahoo! Finance Canada
Fennec Pharmaceuticals Announces Oral Presentation of Detailed Results from Investigator-Initiated Phase 2 STS-J01 Clinical Study of Pedmark® in Japan at SIOP 2026 - Yahoo Finance
FENC 8-K FilingsFennec Pharmaceuticals Inc. SEC 8-K - Stock Titan
Fennec Pharmaceuticals (FENC) director exercises options, then sells matching shares - stocktitan.net
Director at Fennec Pharmaceuticals (NASDAQ: FENC) plans to sell 15,545 shares - Stock Titan
FENC FINAL DEADLINE MONDAY: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Fennec Pharmaceuticals Inc. Investors with Losses to Secure Counsel Before Important April 11 Deadline in Securities Class ActionFENC - TMX Newsfile
FENC Q2 2026 Earnings: EPS Tops Estimates by 400% Despite Modest Stock PullbackGuidance vs Actual - dars.gov.et
Why Fennec Pharmaceuticals Inc stock plummeted yesterday - Wealth Awesome
(FENC) Risk Channels and Responsive Allocation - Stock Traders Daily
Fennec Pharmaceuticals Stock Price Forecast. Should You Buy FRX.TO? - StockInvest.us
What's Going On With Fennec Pharmaceuticals Inc Stock Thursday? - Wealth Awesome
Fennec Pharmaceuticals Insider Rosty Raykov Reports Share Vesting and Sale - kalkinemedia.com
Former Fennec (NASDAQ: FENC) director lines up $121K stock sale - Stock Titan
Former Fennec Pharma (NASDAQ: FENC) director sells 10,000 shares under 10b5-1 plan - Stock Titan
Fennec CCO receives 168 shares at zero cost - Stock Titan
Fennec Pharma CEO gains 1,159-share award - Stock Titan
Fennec Pharma (NASDAQ: FENC) officer to sell 12,000 shares - Stock Titan
Fennec (NASDAQ: FENC) CMO sells 12,000 vested shares in an August 31 trade not tied to a preset Rule 10b5-1 plan. - Stock Titan
Trade Alert: Chief Financial Officer Of Fennec Pharmaceuticals Robert Andrade Has Sold Stock - webull.com
Fennec Pharma (NASDAQ: FENC) CFO sells 75K shares in plan trade - Stock Titan
Fennec Pharma (NASDAQ: FENC) officer to sell 75,000 shares - Stock Titan
Fennec Pharmaceuticals Inc. Revenue Breakdown – NASDAQ:FENC - TradingView
Fennec (FENC) Results Review: Reported EPS Tops Expectations in the Latest Reading; Share Response: The Share Price Sheds 4.63% at the CloseEPS Estimate Trend - vinanet.vn
Fennec (FENC) Results Check: Profit Per Share Clears Its Benchmark on the Day; Investor Response - vinanet.vn
Fennec (FENC) Results Check: Profit Per Share Clears Its Benchmark on the Day; Investor Response: Shares Move 0.51% LowerEarnings Growth Forecast - careplusvn.com
Fennec (FENC) Technical Check: Adds 0.51% to Close at $11.89 at the Close; Current Setup: the Supplied Trading Band Runs From $11.30 to $12.48Throwback Trade - vinanet.vn
Jessica Vargas Appointed Vice President of Human Resources at Fennec Pharmaceuticals - hrtoday.in
(FENC) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Fennec Pharmaceuticals (FENC): Southpoint group files 13G/A showing 0% ownership - Stock Titan
Fennec Pharmaceuticals (FENC) Gets a Buy from Maxim Group - The Globe and Mail
Solas Capital Management (FENC) reports 1.89M Fennec shares, a 5.4% ownership stake - Stock Titan
Results: Fennec Pharmaceuticals Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates - Moomoo
Results: Fennec Pharmaceuticals Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts - simplywall.st
Fennec Pharmaceuticals (FENC) Stock Sees Fair Value Lift As Analysts Raise PEDMARK Views - Yahoo Finance
Fennec Pharmaceuticals Announces Q2 2026 Net Income and Revenue Growth - Kalkine Media
Fennec Pharmaceuticals (FENC) Stock Jumps As Profitability Raises A Bigger Question - webull.com
Fennec Pharmaceuticals (FENC) gains 9.6% stakeholder via Rosalind Advisors - Stock Titan
Fennec Pharmaceuticals (FENC) Gets a Buy from Wedbush - The Globe and Mail
B. Riley Financial Reaffirms "Buy" Rating for Adherex Technologies (NASDAQ:FENC) - MarketBeat
Wedbush Boosts Adherex Technologies (NASDAQ:FENC) Price Target to $16.00 - MarketBeat
Fennec: The Turnaround Is Real, But The Stock Prices In Perfection (Downgrade) - Seeking Alpha
Why Fennec Pharmaceuticals Inc stock surged yesterday - Wealth Awesome
B. Riley Adjusts Fennec Pharmaceuticals Price Target to $18 From $16, Maintains Buy Rating - marketscreener.com
Finanzdaten der Fennec Pharmaceuticals Inc-Aktie (FENC)
Umsatz
Nettogewinn
Free Cashflow
ENV
Fennec Pharmaceuticals Inc-Aktie (FENC) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Brughera Marco Maria | Director |
Sep 15 '26 |
Sale |
10.29 |
15,545 |
159,958 |
0 |
0.05%
0.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):